Cargando…
Amantadine in Treatment of Dysthymia—The Pilot Case Series Study
Dysthymia is a common chronic mood disorder in which isolated symptoms of depression persist for at least 2 years. Despite the many medications recommended for the treatment of dysthymia, no recommendations have yet been made for the treatment of patients who fail to achieve clinical improvement. Th...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10301632/ https://www.ncbi.nlm.nih.gov/pubmed/37375844 http://dx.doi.org/10.3390/ph16060897 |
_version_ | 1785064858671120384 |
---|---|
author | Krzystanek, Marek Martyniak, Ewa Pałasz, Artur Skałacka, Katarzyna Chwalba, Artur Wierzbiński, Piotr |
author_facet | Krzystanek, Marek Martyniak, Ewa Pałasz, Artur Skałacka, Katarzyna Chwalba, Artur Wierzbiński, Piotr |
author_sort | Krzystanek, Marek |
collection | PubMed |
description | Dysthymia is a common chronic mood disorder in which isolated symptoms of depression persist for at least 2 years. Despite the many medications recommended for the treatment of dysthymia, no recommendations have yet been made for the treatment of patients who fail to achieve clinical improvement. This justifies attempts to identify second-line drugs for the treatment of dysthymia. In an open and naturalistic case study, five patients diagnosed with dysthymia in whom at least one antidepressant treatment was ineffective were treated with amantadine. In the age- and gender-matched external control group, patients were treated with sertraline at 100 mg/day. Depressive symptoms were assessed using HDRS-17. Two men and three women were treated with 100 mg amantadine for 3 months with 3–5 months follow-up. After 1 month of treatment with amantadine, a significant reduction in the intensity of depressive symptoms was achieved in all patients, and the clinical improvement increased over the next 2 months of treatment. No deterioration in well-being was observed in any patient after discontinuation of amantadine. The effect of amantadine treatment was comparable to that of sertraline treatment in patients with dysthymia who improved with this drug. The present study indicates that amantadine is an effective and well-tolerated drug in the treatment of dysthymia. Amantadine may be associated with a quick improvement in symptoms in the treatment of dysthymia. Treatment with this drug seems to be associated with good tolerability and persistency of the therapeutic effect after the discontinuation of the treatment. |
format | Online Article Text |
id | pubmed-10301632 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-103016322023-06-29 Amantadine in Treatment of Dysthymia—The Pilot Case Series Study Krzystanek, Marek Martyniak, Ewa Pałasz, Artur Skałacka, Katarzyna Chwalba, Artur Wierzbiński, Piotr Pharmaceuticals (Basel) Communication Dysthymia is a common chronic mood disorder in which isolated symptoms of depression persist for at least 2 years. Despite the many medications recommended for the treatment of dysthymia, no recommendations have yet been made for the treatment of patients who fail to achieve clinical improvement. This justifies attempts to identify second-line drugs for the treatment of dysthymia. In an open and naturalistic case study, five patients diagnosed with dysthymia in whom at least one antidepressant treatment was ineffective were treated with amantadine. In the age- and gender-matched external control group, patients were treated with sertraline at 100 mg/day. Depressive symptoms were assessed using HDRS-17. Two men and three women were treated with 100 mg amantadine for 3 months with 3–5 months follow-up. After 1 month of treatment with amantadine, a significant reduction in the intensity of depressive symptoms was achieved in all patients, and the clinical improvement increased over the next 2 months of treatment. No deterioration in well-being was observed in any patient after discontinuation of amantadine. The effect of amantadine treatment was comparable to that of sertraline treatment in patients with dysthymia who improved with this drug. The present study indicates that amantadine is an effective and well-tolerated drug in the treatment of dysthymia. Amantadine may be associated with a quick improvement in symptoms in the treatment of dysthymia. Treatment with this drug seems to be associated with good tolerability and persistency of the therapeutic effect after the discontinuation of the treatment. MDPI 2023-06-19 /pmc/articles/PMC10301632/ /pubmed/37375844 http://dx.doi.org/10.3390/ph16060897 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Communication Krzystanek, Marek Martyniak, Ewa Pałasz, Artur Skałacka, Katarzyna Chwalba, Artur Wierzbiński, Piotr Amantadine in Treatment of Dysthymia—The Pilot Case Series Study |
title | Amantadine in Treatment of Dysthymia—The Pilot Case Series Study |
title_full | Amantadine in Treatment of Dysthymia—The Pilot Case Series Study |
title_fullStr | Amantadine in Treatment of Dysthymia—The Pilot Case Series Study |
title_full_unstemmed | Amantadine in Treatment of Dysthymia—The Pilot Case Series Study |
title_short | Amantadine in Treatment of Dysthymia—The Pilot Case Series Study |
title_sort | amantadine in treatment of dysthymia—the pilot case series study |
topic | Communication |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10301632/ https://www.ncbi.nlm.nih.gov/pubmed/37375844 http://dx.doi.org/10.3390/ph16060897 |
work_keys_str_mv | AT krzystanekmarek amantadineintreatmentofdysthymiathepilotcaseseriesstudy AT martyniakewa amantadineintreatmentofdysthymiathepilotcaseseriesstudy AT pałaszartur amantadineintreatmentofdysthymiathepilotcaseseriesstudy AT skałackakatarzyna amantadineintreatmentofdysthymiathepilotcaseseriesstudy AT chwalbaartur amantadineintreatmentofdysthymiathepilotcaseseriesstudy AT wierzbinskipiotr amantadineintreatmentofdysthymiathepilotcaseseriesstudy |